Hangzhou Tigermed Consulting Co. Ltd.
(OTC: HNGZY)
|
4:43 PM UTC, 12/19/23 | |||
---|---|---|---|---|
Last: $4.20 | Change: -0.20 | %Change: -4.55% | Volume: 612 |
Open: | $ 4.28 | Volume: | 612 | |
---|---|---|---|---|
High: | $ 4.28 | Yield(%) | 1.65 | |
Low: | $ 4.20 | P/E Ratio (ttm): | 10.24 | |
Dividend ($): | 0.06 | Market Cap ($): | 417.39M | |
EPS ($) | 0.35 | Shares Out: | 123.12M |
% Price Change (last 4 weeks): | -20.82 |
---|---|
% Price Change (last 13 weeks): | -10.62 |
% Price Change (last 26 weeks): | -22.52 |
% Price Change (last 52 weeks): | -42.29 |
% Price Change (year to date): | -25.12 |
Return on Equity (%): | 9.87 |
---|---|
Return on Assets (%): | 7.03 |
Return on Invested Capital (%): | 15.10 |
Gross Profit Margin (%): | 38.20 |
---|---|
Net Profit Margin (%): | 27.44 |
Operating Profit Margin (%): | 22.22 |
|
|
50-day Moving Average: | $n/a |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | n/a |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $7.78 |
52-wk low: | $4.20 |
Bid: | $n/a |
Ask: | $n/a |
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
|
Hangzhou Tigermed Consulting Co. Ltd.
20/F Block 8, Room 2001-2010 No.19 Jugong Road, Xixiang Street Binjiang District Hangzhou ZH 310051 Phone: 0.571.28887227 Fax: 0.571.88211196 http://www.tigermed.net |
Earnings (1year) ($): | n/a |
---|---|
Annual Dividend ($): | 0.06 |
Current P/E Ratio (ttm): | 10.24 |
Book Value ($): | 24.13 |
Cash Flow ($): | 2.71 |
Price/Earnings (x): | 10.24 |
---|---|
Price/Sales (x): | 3.76 |
Price/Book (x): | 0.19 |
Price/Cash Flow (x): | 25.30 |
Quick Ratio (x): | 2.73 |
---|---|
Current Ratio (x): | 2.74 |
LT Debt/Equity (x): | 4.07 |
Total Debt/Equity (x): | 15.88 |